Biomedical Engineering Reference
In-Depth Information
30. Hoarau, D.; Delmas, P.; David, S.; Roux, E.; Leroux, J. C. Novel Long Circulating Lipid
Nanocapsules.
Pharm. Res.
2004,
21,
1783-1789.
31. Das, S.; Jagan, L.; Isiah, R.; Rajech, B.; Backianathan, S.; Subhashini, J. Nanotechnology
in Oncology: Characterization and In Vitro Release Kinetics of Cisplatin-Loaded Albumin
Nanoparticles: Implications in Anticancer Drug Delivery.
Indian J. Pharmacol.
2011,
43,
409-413.
32. Koo, O.; Rubinstein, I.; Onyuksel, H. Camptothecin in Sterically Stabilized Phospholipid
Micelles: A Novel Nanomedicine.
Nanomedicine
2005,
1,
77-84.
33. Kristl, J.; Volk, B.; Gasperlin, M.; Sentjurc, M.; Jurkovic, P. Effect of Colloidal Carriers on
Ascorbyl Palmitate Stability.
Eur. J. Pharm. Sci.
2003,
19,
181-189.
34. Arnedo, A.; Irache, J. M.; Merodio, M.; Espuelas, M.; Millan, S. Albumin Nanoparticles
Improved the Stability, Nuclear Accumulation and Anticytomegaloviral Activity of a Phos-
phodiester Oligonucleotide.
J. Contr. Release
2004,
94,
217-227.
35. Zhang, J. A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Devel-
opment and Characterization of a Novel Cremophor
®
EL Free Liposome-Based Paclitaxel
(Lep-Etu) Formulation.
Eur. J. Pharm. Biopharm.
2005,
59,
177-187.
36. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.;
O'Shaughnessy, J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with
Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer.
J. Clin. Oncol.
2005,
23,
7794-7803.
37. Blum, J. L.; Savin, M. A.; Edelman, G.; Pippen, J. E.; Robert, N. J.; Geister, B. V.; Kirby,
R. L.; Clawson, A.; O'shaughnessy, J. A. Phase II Study of Weekly Albumin-Bound Pacli-
taxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes.
Clin. Breast
Cancer
2007,
7,
850-856.
38. Krishnadas, A.; Rubinstein, I.; Onyuksel, H. Sterically Stabilized Phospholipid Mixed
Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs.
Pharm. Res.
2003,
20,
297-302.
39. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The Drawbacks and
Advantages of Vehicle Selection for Drug Formulation.
Eur. J. Cancer
2001,
37,
1590-1598.
40. tenTije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological Effects of Formu-
lation Vehicles: Implications for Cancer Chemotherapy.
Clin. Pharmacokinet.
2003,
42,
665-685.
41. Hatefi, A.; Amsden, B. Camptothecin Delivery Methods.
Pharm. Res.
2002,
19,
1389-1399.
42. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized Micellar Systems for Cancer
Targeted Drug Delivery.
Pharm. Res.
2007,
24,
1029-1046.
43. Huuskonen, J.; Salo, M.; Taskinen, J. Neural Network Modeling for Estimation of the Aque-
ous Solubility of Structurally Related Drugs.
J. Pharm. Sci.
1997,
86,
450-454.
44. Sakamoto, J. H.; van de Ven, A. L.; Godin, B.; Blanco, E.; Serda, R. E.; Grattoni, A.; Ziemys,
A.; Bouamrani, A.; Hu, T.; Ranganathan, S. I.; De Rosa, E.; Martinez, J. O.; Smid, C. A.;
Buchanan, R.; Lee, S. Y.; Srinivasan, S.; Landry, M.; Meyn, A.; Tasciotti, E.; Li, X.; Decuzzi,
P.; Ferrari, M. Review: Enabling Individualized Therapy through Nanotechnology.
Pharm.
Res.
2010,
62,
57-89.
45. Ferrari, M. Nanovector Therapeutics.
Curr. Opin. Chem. Biol.
2005,
9,
343-346.
46. Canal, P.; Gamelin, E.; Vassal, G.; Robert, J. Benefits of Pharmacological Knowledge in the
Design and Monitoring of Cancer Chemotherapy.
Pathol. Oncol. Res.
1998,
4,
171-178.
47. Tallaj, J. A.; Franco, V.; Rayburn, B. K.; Pinderski, L.; Benza, R. L.; Pamboukian, S., et al.
Response of Doxorubicin Induced Cardiomyopathy to the Current Management Strategy of
Heart Failure.
J. Heart Lung Transplant.
2005,
24,
196-201.
